Lonza

Lonza provides a comprehensive suite of biologics services, including mammalian and microbial biopharmaceuticals, ADCs, and drug product manufacturing. The company offers small molecule services that span from drug substance development to commercial production, with expertise in highly potent APIs and bioavailability enhancement. Lonza’s cell and gene therapy services cover process development, cGMP manufacturing, and regulatory consulting. Additionally, Lonza manufactures capsules and health ingredients, catering to both the pharmaceutical and nutraceutical industries. The company is also involved in mRNA and LNP development and manufacturing, offering services from pre-clinical to commercial stages. Lonza specializes in bioconjugates services, particularly ADCs, providing end-to-end solutions from early development to commercial manufacturing. Committed to sustainability, Lonza has initiatives aimed at reducing its environmental impact, including targets for energy, waste, and greenhouse gas emissions reduction. Operating globally, Lonza has a network of facilities across North America, Europe, and Asia, offering extensive regulatory expertise and market access. The company also provides comprehensive regulatory affairs services, supporting clients through clinical trials, commercial applications, and product registration.